Brought to you by:

Cell & Gene Therapy

Fabry disease
Biotech

Cash-strapped Sangamo seeks partner for new gene therapy

Sangamo Therapeutics’ investigational gene therapy appears to improve kidney function at 52 weeks for patients with a rare genetic disorder.
Gabrielle Masson Jun 24, 2025 11:53am
Small white blocks with black text that say Diabetes Type 1 in all caps surrounded by syringes containing a blue liquid th

Vertex diabetes islet cell therapy improves blood sugar levels

Jun 23, 2025 4:21am
Reorganization team change restructure

Industry disappointed as FDA reportedly puts Verdun on leave

Jun 20, 2025 1:53am
Eli Lilly

Eli Lilly pays $1B upfront to buy gene editing partner Verve

Jun 17, 2025 4:35am
Redbrick building with Sarepta name and logo
Favicon Fierce Pharma

2nd patient dies after Sarepta's DMD gene therapy Elevidys

Jun 16, 2025 10:58am
Graphic of a drop of blood made up of small data points and nodes

J&J lymphoma CAR-T hits 100% ORR in 10 patients

Jun 13, 2025 1:22pm
More News

SpliceBio secures $135M series B for eye gene therapy trials

Jun 11, 2025 3:00am

As investors pivot from cell therapy, Immatics keeps the faith

Jun 6, 2025 3:50am

At cell and gene roundtable, officials pledge to slash regulations

Jun 5, 2025 2:50pm

RegenXBio links DMD gene therapy to improved outcomes

Jun 5, 2025 8:52am